Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (HK:1801)
:1801
1801 Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
1801 Stock 12 Month Forecast
Average Price Target
HK$53.36
▲(15.49% Upside)
| Highest Price TargetHK$61.71 | Average Price TargetHK$53.36 | Lowest Price TargetHK$40.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
CMB International Securities
Reiterated
03/31/25
J.P. Morgan
Reiterated
03/28/25
Bernstein
Reiterated
03/28/25
Nomura
Reiterated
02/18/25
Goldman Sachs
Reiterated
02/05/25
Jefferies
Reiterated
01/22/25
Bank of America Securities
Reiterated
01/03/25
Morgan Stanley
HK$66.5
Buy
43.94%
Upside
Assigned
12/23/24
Morgan Stanley Reiterates Overweight Rating on Innovent Biologics Inc. (1801:HK) (IVBXF)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$66.50 price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF).
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
CMB International Securities
Reiterated
03/31/25
J.P. Morgan
Reiterated
03/28/25
Bernstein
Reiterated
03/28/25
Nomura
Reiterated
02/18/25
Goldman Sachs
Reiterated
02/05/25
Jefferies
Reiterated
01/22/25
Bank of America Securities
Reiterated
01/03/25
Morgan Stanley
HK$66.5
Buy
43.94%
Upside
Assigned
12/23/24
Morgan Stanley Reiterates Overweight Rating on Innovent Biologics Inc. (1801:HK) (IVBXF)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$66.50 price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF).
1801 Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
7
5
7
8
9
Buy
0
0
0
0
0
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
5
7
8
9
Each month's total comprises the sum of three months' worth of ratings.
1801 Financial Forecast
1801 Stock Forecast FAQ
What is HK:1801’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is HK$53.36.
What is HK:1801’s upside potential, based on the analysts’ average price target?
Innovent Biologics has 15.49% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Innovent Biologics a Buy, Sell or Hold?
Innovent Biologics has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Innovent Biologics’s share price target?
The average share price target for Innovent Biologics is HK$53.36. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$61.71 ,and the lowest forecast is HK$40.00. The average share price target represents 15.49% Increase from the current price of HK$46.2.
The highest analyst share price target is HK$61.71 ,and the lowest forecast is HK$40.00. The average share price target represents 15.49% Increase from the current price of HK$46.2.
What do analysts say about Innovent Biologics?
Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of Innovent Biologics?
To buy shares of HK:1801, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.